Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Repurchased Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Lisata Therapeutics (LSTA) Shares Issued (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Shares Issued readings, the most recent being $1.1 million for Q4 2025.

For the quarter ending Q4 2025, Shares Issued rose 279.43% year-over-year to $1.1 million, compared with a TTM value of $1.9 million through Dec 2025, up 247.48%, and an annual FY2025 reading of $844000.0, changed N/A over the prior year.
Shares Issued hit $1.1 million in Q4 2025 for Lisata Therapeutics, up from $881510.0 in the prior quarter.
The five-year high for Shares Issued was $1.1 million in Q4 2025, with the low at -$845000.0 in Q2 2023.
Median Shares Issued over the past 3 years was $270774.0 (2023), compared with a mean of $194685.7.
The largest YoY upside for Shares Issued was 297.78% in 2024 against a maximum downside of 0.0% in 2024.
Year by year, Shares Issued stood at -$142000.0 in 2023, then soared by 297.78% to $280848.0 in 2024, then surged by 279.43% to $1.1 million in 2025.
According to Business Quant data, Shares Issued over the past three periods came in at $1.1 million, $881510.0, and -$242343.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.